Show Summary Details
Page of

Valproate for Generalized and Unclassifiable Epilepsy: Arm B of the SANAD Trial 

Valproate for Generalized and Unclassifiable Epilepsy: Arm B of the SANAD Trial
Chapter:
Valproate for Generalized and Unclassifiable Epilepsy: Arm B of the SANAD Trial
Author(s):

Shivani Ghoshal

DOI:
10.1093/med/9780199377527.003.0005
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 16 September 2019

This chapter provides a summary of a landmark study in epilepsy. What are the relative efficacies and long-term effects of valproate, lamotrigine, and topiramate for patients with generalized onset seizures? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. Researchers found that in comparison to lamotrigine and topiramate, valproate remains a superior treatment for time to treatment failure in patients with generalized seizures and idiopathic generalized epilepsy and should remain a first-line therapy for these patients. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.